FDA Green Light: Instil Bio's Dual-Action Cancer Drug Advances to Clinical Trials for Hard-to-Treat Tumors - Stock Titan
  'Operation Blue Thunder' nets 68 arrests in Indiana drug crackdown - FOX 55 Fort Wayne
  Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease - Ocugen
  Tecovirimat (TPOXX) for Treatment of Mpox - Centers for Disease Control and Prevention
  The National Cancer Institute’s Investigational New Drug program is imperative for public good - STAT
  Investigational New Drug CDMO Market Size to Hit USD 10.26 Bn by 2034 - Precedence Research
  Rebel Medicine Announces Series A Financing and Investigational New Drug (IND) Application Opening to Advance Non‑Opioid Pain Therapeutic into Clinical Development - PR Newswire
  Archeus Technologies Receives FDA Clearance of Investigational New Drug Application for ART-101 in Development for the Treatment of Prostate Cancer - Business Wire